Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRONTSE:GUDNYSE:RIVNASDAQ:TLRY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRONCronos Group$1.88+1.6%$1.83$1.60▼$3.14$724.57M1.021.38 million shs2.78 million shsGUDKnight TherapeuticsC$6.08+1.5%C$5.83C$5.09▼C$6.45C$614.99M0.568,507 shs30,855 shsRIVRiverNorth Opportunities Fund$11.49-0.3%$11.55$10.11▼$12.96N/AN/A82,865 shs98,474 shsTLRYTilray$0.49-1.0%$0.61$0.43▼$2.34$488.25M1.8829.01 million shs27.48 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRONCronos Group+1.09%+4.52%+3.35%-1.60%-27.45%GUDKnight Therapeutics+1.18%+4.72%-1.64%+4.17%+3.45%RIVRiverNorth Opportunities Fund+1.86%+3.97%-2.66%-3.39%-1.71%TLRYTilray+2.70%+6.97%-26.09%-53.57%-72.33%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRONCronos Group1.5122 of 5 stars2.04.00.00.02.40.01.3GUDKnight Therapeutics1.416 of 5 stars2.60.00.00.00.63.30.6RIVRiverNorth Opportunities FundN/AN/AN/AN/AN/AN/AN/AN/ATLRYTilray1.5617 of 5 stars3.12.00.00.01.30.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRONCronos Group 0.00N/A$3.5086.17% UpsideGUDKnight Therapeutics 3.25BuyC$7.4822.94% UpsideRIVRiverNorth Opportunities Fund 0.00N/AN/AN/ATLRYTilray 2.25Hold$1.92295.11% UpsideCurrent Analyst Ratings BreakdownLatest RIV, CRON, GUD, and TLRY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/14/2025TLRYTilrayRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral4/9/2025TLRYTilrayPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$2.00 ➝ $1.003/25/2025GUDKnight TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuyC$6.25 ➝ C$7.453/21/2025GUDKnight TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold3/11/2025GUDKnight TherapeuticsResearch CapitlSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy(Data available from 4/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRONCronos Group$117.62M6.16N/AN/A$2.87 per share0.66GUDKnight TherapeuticsC$348.70M1.76C$1.58 per share3.85C$7.65 per share0.79RIVRiverNorth Opportunities Fund$44.13MN/AN/AN/AN/AN/ATLRYTilray$210.48M2.32N/AN/A$4.14 per share0.12Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRONCronos Group-$73.96M$0.10N/A62.671.74-42.65%-2.56%-2.47%5/8/2025 (Estimated)GUDKnight Therapeutics-C$30.73M-C$0.30N/A∞N/A-8.81%-4.04%0.51%N/ARIVRiverNorth Opportunities FundN/AN/A0.00∞N/AN/AN/AN/AN/ATLRYTilray-$244.98M-$1.05N/AN/AN/A-30.95%-4.40%-3.57%N/ALatest RIV, CRON, GUD, and TLRY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/8/2025Q3 2025TLRYTilray-$0.04-$0.10-$0.06-$0.87$213.38 million$185.78 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRONCronos GroupN/AN/AN/AN/AN/AGUDKnight TherapeuticsN/AN/AN/AN/AN/ARIVRiverNorth Opportunities Fund$1.5413.40%-8.84%N/AN/ATLRYTilrayN/AN/AN/AN/AN/ALatest RIV, CRON, GUD, and TLRY DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/4/2025RIVRiverNorth Opportunities Fundmonthly$0.127713%6/13/20256/13/20256/30/20254/3/2025RIVRiverNorth Opportunities Fundmonthly$0.127713%6/13/20256/13/20256/30/20254/9/2025RIVRiverNorth Opportunities Fund$0.127714.71%4/15/20254/16/20254/30/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRONCronos GroupN/A24.2423.05GUDKnight Therapeutics7.523.361.79RIVRiverNorth Opportunities FundN/AN/AN/ATLRYTilray0.102.541.58Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRONCronos Group8.71%GUDKnight Therapeutics12.58%RIVRiverNorth Opportunities FundN/ATLRYTilray9.35%Insider OwnershipCompanyInsider OwnershipCRONCronos Group6.90%GUDKnight Therapeutics45.62%RIVRiverNorth Opportunities FundN/ATLRYTilray0.87%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRONCronos Group450385.41 million356.14 millionOptionableGUDKnight Therapeutics725101.15 millionN/ANot OptionableRIVRiverNorth Opportunities FundN/AN/AN/ANot OptionableTLRYTilray2,6501.01 billion929.50 millionOptionableRIV, CRON, GUD, and TLRY HeadlinesRecent News About These CompaniesTilray (NASDAQ:TLRY) Trading 0.2% Higher - Still a Buy?April 30 at 3:12 PM | marketbeat.com10 Barrel Brewing Launches Non-Alcoholic Apocalypse IPA, a Bold Craft Brew for Your Next AdventureApril 30 at 7:00 AM | globenewswire.comTilray (NASDAQ:TLRY) Shares Down 3.3% - Time to Sell?April 29 at 3:36 PM | marketbeat.comTilray Brands Could Bounce BigApril 28 at 7:00 AM | seekingalpha.comWidmer Brothers Brewing Celebrates 40th AnniversaryApril 28 at 7:00 AM | globenewswire.comTilray (NASDAQ:TLRY) Stock Price Up 0.8% - Still a Buy?April 26, 2025 | marketbeat.comTilray (NASDAQ:TLRY) Stock Price Up 1.8% - Time to Buy?April 26, 2025 | marketbeat.comTilray is exiting New Zealand’s medical cannabis market to focus on AustraliaApril 25, 2025 | mjbizdaily.comTilray (NASDAQ:TLRY) Shares Up 2% - Should You Buy?April 25, 2025 | marketbeat.comTilray’s Terrapin Beer partners with OrvisApril 24, 2025 | markets.businessinsider.comTilray (NASDAQ:TLRY) Trading Up 0.8% - Still a Buy?April 24, 2025 | marketbeat.comTerrapin Beer Co. Celebrates 23 Years of Craft Beer and Environmental Stewardship with Terraprint Initiative and Orvis PartnershipApril 24, 2025 | globenewswire.comTilray (NASDAQ:TLRY) Trading 1.7% Higher - Here's WhyApril 23, 2025 | marketbeat.comTilray’s Breckenridge Distillery announces re-release of Cognac Cask FinishApril 23, 2025 | markets.businessinsider.comBreckenridge Distillery Announces Re-Release of Award-Winning Cognac Cask Finish WhiskeyApril 23, 2025 | globenewswire.comTilray (NASDAQ:TLRY) Trading Down 1.6% - Here's What HappenedApril 22, 2025 | marketbeat.comApril 2025's Canadian Cannabis Stock Picks: Growth and OpportunityApril 22, 2025 | marijuanastocks.comTilray Brands Announces Reverse Stock SplitApril 21, 2025 | baystreet.caPromising Cannabis Stocks To Keep An Eye On - April 20thApril 21, 2025 | marketbeat.comBest Cannabis Stocks To Keep An Eye On - April 19thApril 20, 2025 | marketbeat.comTilray (NASDAQ:TLRY) Trading Down 5.4% - What's Next?April 19, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBroadcom's VMware Deal Lifts AVGO Despite Complaints By Leo Miller | April 28, 2025View Broadcom's VMware Deal Lifts AVGO Despite Complaints Broadcom’s VMware Strategy Could Fuel the Next AVGO RallyBy Leo Miller | April 3, 2025View Broadcom’s VMware Strategy Could Fuel the Next AVGO Rally4 Dividend Growth Stocks the Trade Tariffs Can’t TouchBy Thomas Hughes | April 7, 2025View 4 Dividend Growth Stocks the Trade Tariffs Can’t TouchTariffs, Spin-Out, and R2 Updates Are Positive Signs for RivianBy Leo Miller | April 3, 2025View Tariffs, Spin-Out, and R2 Updates Are Positive Signs for RivianTop 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or HoldBy Thomas Hughes | April 14, 2025View Top 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or HoldRIV, CRON, GUD, and TLRY Company DescriptionsCronos Group NASDAQ:CRON$1.88 +0.03 (+1.62%) As of 04:00 PM EasternCronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.Knight Therapeutics TSE:GUDC$6.08 +0.09 (+1.50%) As of 04:00 PM EasternKnight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company provides Ladecvina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for vasomotor symptoms; Fibridoner for idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.RiverNorth Opportunities Fund NYSE:RIV$11.49 -0.04 (-0.35%) As of 03:49 PM EasternRiverNorth Opportunities Fund, Inc. is a close ended equity mutual fund co- launched and co- managed by ALPS Advisors, Inc. and RiverNorth Capital Management, LLC. It invests in the equity markets. The fund seeks to invest in stocks of companies operating across the diversified sectors. RiverNorth Opportunities Fund, Inc. was formed on December 24, 2015 and is domiciled in the United States.Tilray NASDAQ:TLRY$0.49 0.00 (-0.96%) As of 04:00 PM EasternTilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hims & Hers Stock Soars on Novo Nordisk Collaboration 3 Dividend Kings Outshining the Market in 2025 Tesla's Band-Aid Has Been Ripped Off: Rally Mode Engaged Amazon's Earnings Will Make or Break the Stock's Comeback Why D-Wave's Project With Davidson Is a Game-Changer For Quantum NXP Semiconductors: A Buy-and-Hold Stock in the Buy Zone Joby Aviation Shares Eye Breakout After Transition Flight Win Altria’s Resilient Strategy Keeps It a Top Dividend Play in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
